Impact of new first-in-class medical therapy in obstructive HCM

Name: Impact of new first-in-class medical therapy in obstructive HCM
Uploaded: 2022-04-03T02:00:00+00:00
Duration: 1 min 57 s
Description: ACC 2022 Joseph Cleveland, discussant of the VALOR-HCM trial, gives his view on the impact of this trial on the treatment of obstructive hypertrophic cardi

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
ACC 2026 Clinical Insights: Advancing Cardiovascular Care
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
Joseph Rossano, MD
- Joseph Rossano, MD
Precision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
Precision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
Hypertrophic Cardiomyopathy
Precision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
Ahmad Masri, MD, MS
- Ahmad Masri, MD, MS
Targeting cardiac energetics with cardiac mitotrope in nonobstructive HCM
Targeting cardiac energetics with cardiac mitotrope in nonobstructive HCM
ACC.24
Targeting cardiac energetics with cardiac mitotrope in nonobstructive HCM
Martin Maron, MD
- Martin Maron, MD
First ESC guidelines on cardiomyopathies - diagnosis
First ESC guidelines on cardiomyopathies - diagnosis
ESC Congress 2023
First ESC guidelines on cardiomyopathies - diagnosis
Elena Arbelo, MD, PhD
- Elena Arbelo, MD, PhD

Impact of new first-in-class medical therapy in obstructive HCM

Recommended

Title